Dermapharm Holding SE (Dermapharm), together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany.
Business Segments
Dermapharm operates through three main business segments: Branded Pharmaceuticals an…
Analysis
Middle-of-the-road
Dermapharm Holding SE is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.
The price is fair. You pay 18.3× its owner earnings: the cash an owner could take out each year, which is in the historically fair zone. At today's price, the market is assuming roughly 5% yearly growth; analysts expect 9%. The price, in other words, assumes less than the experts do.
The trajectory is moderate and the balance sheet is stretched. The company scores 14/20 on our value-creation score: strong value creator. Analyst sentiment is cautious.
Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.
360° rank · history
1007550250
Feb 202623
42
2026
All-time high
42
Jun 2026
All-time low
21
Mar 2026
Average rank
29
across all years
Detailed & Historical Ranks
Deep dive into 15 detailed ranks and 3 years of history.
Current202520242023
Price/Sales
82
—
—
—
Price/Earnings
53
—
—
—
Price/Book
57
—
—
—
Dividend Yield
73
—
—
—
Value (overall)
85
—
—
—
Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.